Antiviral treatment of cytomegalovirus infection

Infectious Disorders - Drug Targets

Volumn 11, Issue 5, 2011, Pages 475-503

  Ahmed, Amina ^a  

^a Levine Children's Hospital at Carolina Healthcare System   (United States)

Author keywords

Cidofovir; Cytomegalovirus; Foscarnet; Ganciclovir; Resistance; Valganciclovir

Indexed keywords

ACICLOVIR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CILASTATIN PLUS IMIPENEM; DIDANOSINE; FOMIVIRSEN; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; PROBENECID; VALACICLOVIR; VALGANCICLOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CARCINOGENESIS; COMA; CONFUSION; CONGENITAL INFECTION; CONVULSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMBRYOTOXICITY; ENDOPHTHALMITIS; FEVER; GENITAL ULCER; GRAFT RECIPIENT; GRAND MAL SEIZURE; GRANULOCYTOPENIA; HALLUCINATION; HEADACHE; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INJECTION SITE INFLAMMATION; INJECTION SITE PHLEBITIS; INTERSTITIAL NEPHRITIS; INTRAOCULAR HYPOTENSION; IRITIS; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MALABSORPTION; MENTAL HEALTH; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; RASH; REPRODUCTIVE TOXICITY; SEIZURE; SENSORY SYSTEM; SIDE EFFECT; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREMOR; UREMIA; UVEITIS; VERTICAL TRANSMISSION; VIRUS REPLICATION; VITREOUS HEMORRHAGE; VOMITING;

EID: 80054111578     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152611797636640     Document Type: Article

References (154)

1. Gandhi, M.K.; Khanna, R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis., 2004, 4 (12), 725-738.
2. Chee, M.S.; Bankier, A.T.; Beck, S.; Bohni, R.; Brown, C.M.; Cerny, R.; Horsnell, T.; Hutchison III, C.A.; Kouzarides, T.; Martignetti, J.A.; Preddie, E.; Satchwell, S.C.; Tomlinson, P.; Weston, K.M.; Barrell, B.G. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD19. Curr. Top. Microbiol. Immunol., 1990, 154, 125-169.
3. Kimberlin, D.W. Antiviral therapy for cytomegalovirus infections in pediatric patients. Semin. Pediatr. Infect. Dis., 2002, 13 (1), 22-30.
4. Staras, S.A.S.; Dollard, S.C.; Redford, K.W.; Flanders, W.D.; Pass, R.F.; Cannon, M.J. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin. Infect. Dis., 2006, 43 (9), 1143-1151.
5. Bate, S.L.; Dollard, S.C.; Cannon, M.J. Cytomegalovirus seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988-2004. Clin. Infect. Dis., 2010, 50 (11), 1439-1447.
6. Singh, N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev. Med. Virol., 2006, 16 (5), 281-287.
7. Snydman, D.R. Epidemiology of infections after solid-organ transplantation. Clin. Infect. Dis., 2001, 33 (Suppl 1), S5-S8.
8. Lischka, P.; Zimmermann, H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr. Opin. Pharmacol., 2008, 8 (5), 541-548.
9. Ross, S.A.; Boppana, S.B. Congenital cytomegalovirus infection: outcome and diagnosis. Semin. Pediatr. Infect. Dis., 2005, 16 (1), 44-49.
10. Kimberlin, D.W.; Lin, C-Y.; Sánchez, P.J.; Demmler, G.J.; Dankner, W.; Shelton, M.; Jacobs, R.F.; Vaudry, W.; Pass, R.F.; Kiell, J.M.; Soong, S-J.; Whitley, R.J. for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr., 2003, 143 (1), 16-25.
11. Elion, G.B.; Furman, P.A.; Fyfe, J.A.; de Miranda, P.; Beauchamp, L.; Schaeffer, H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. USA, 1977, 74 (12), 5716-5720.
12. Andrei, G.; De Clercq, E.; Snoeck, R. Drug targets in cytomegalovirus infection. Infect. Disord. Drug Targets, 2009, 9 (2), 201-222.
13. Andrei, G.; De Clercq, E.; Snoeck, R. Novel inhibitors of human CMV. Curr. Opin. Investig. Drugs, 2008, 9 (2), 132-145.
14. Biron, K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res., 2006, 71 (2-3), 154-163.
15. Steininger, C. Novel therapies for cytomegalovirus disease. Recent Pat. Antiinfect. Drug Discov., 2007, 2 (1), 53-72.
16. Wagstaff, A.J.; Faulds, D.; Goa, K.L. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 1994, 47 (1), 153-205.
17. Perry, C.M.; Faulds, D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs, 1996, 52 (5), 754-772.
18. Whitley, R.J.; Gnann, J.W. Jr. Acyclovir: a decade later. N. Engl. J. Med., 1992, 327 (11), 782-789.
19. Package insert. Acyclovir for injection, USP. http://www.bedfordlabs.com/products/inserts/Div-ACYP05.pdf [Accessed 24th September, 2010].
20. Package insert. Valtrex® (valacyclovir hydrochloride). http://us.gsk.com/products/assets/us_valtrex.pdf [Accessed 24th September, 2010].
21. Aoki, F.Y.; Hayden, F.G.; Dolin, R. Antiviral Drugs (Other than Antiretrovirals). In Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed.; Mandell, G.L.; Bennett, J.E.; Dolin, R. Eds.; Churchill Livingstone, Elsevier: Philadelphia, PA 2010, Vol. 1, pp. 565-610.
22. Kimberlin, D.; Powell, D.; Gruber, W.; Diaz, P.; Arvin, A.; Kumar, M.; Jacobs, R.; Van Dyke, R.; Burchett, S.; Soong, S.J.; Lakeman, A.; Whitley, R.; The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eye and mouth: results of a phase I/II trial. Pediatr. Infect. Dis. J., 1996, 15 (3), 247-254.
23. Feinberg, J.E.; Hurwitz, S.; Cooper, D.; Sattler, F.R.; MacGregor, R.R.; Powderly, W.; Holland, G.N.; Griffiths, P.D.; Pollard, R.B.; Youle, M.; Gill, M.J.; Holland, F.J.; Power, M.E.; Owens, S.; Coakley, D.; Fry, J.; Jacobson, M.A.; for the AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J. Infect. Dis., 1998, 177 (1), 48-56.
24. Lowance, D.; Neumayer, H.H.; Legendre, C.M.; Squifflet, J-P.; Kovarik, J.; Brennan, P.J.; Norman, D.; Mendez, R.; Keating, M.R.; Coggon G.L.; Crisp, A.; Lee, I.C. for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N. Engl. J. Med., 1999, 340 (19), 1462-1470.
25. Package insert. Cytovene®-IV (ganciclovir sodium for injection). http://www.gene.com/gene/products/information/cytovene/pdf/pi.p df [Accessed 24th September, 2010].
26. Crumpaker, C.S. Ganciclovir. N. Engl. J. Med., 1996, 335 (10), 721-729.
27. Faulds, D.; Heel, R.C. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs, 1990, 39 (4), 597-638.
28. McGavin, J.K.; Goa, K.L. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs, 2001, 61 (8), 1153-1183.
29. Biron, K.K.; Stanat, S.C.; Sorrell, J.B.; Fyfe, J.A.; Keller, P.M.; Lambe, C.U.; Nelson, D.J. Metabolic activation of the nucleoside analog 9-{[2-hydroxyl-1-(hydroxymethyl)ethoxy]methyl}guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. U.S.A., 1985, 82 (8), 2473-2477.
30. Package insert. Valcyte® (valganciclovir hydrochloride) tablets, Valcyte® (valganciclovir hydrochloride) for oral solution. http://www.gene.com/gene/products/information/valcyte/pdf/pi.pdf [Accessed 24th September, 2010].
31. Marschall, M.; Stamminger, T. Molecular targets for antiviral therapy of cytomegalovirus infections. Future Microbiol., 2009, 4 (6), 731-742.
32. Marx J.L.; Kapusta, M.A.; Patel S.S.; LaBree, L.D.; Walonker, F.; Rao, N.A.; Chong, L.P. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch. Ophthalmol., 1996, 114 (7), 815-820.
33. Trang, J.M.; Kidd, L.; Gruber, W.; Storch, G.; Demmler, G.; Jacobs, R.; Dankner, W.; Starr, S.; Pass, R.; Stagno, S.; Alford, C.; Soong, S.J.; Whitley, R.J.; Sommadossi, J.P.; for the NIAID Collaborative Antiviral Study Group. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin. Pharmacol. Ther., 1993, 53 (1), 15-21.
34. Zhang, D.; Lapeyraque, A.L.; Popon, M.; Loirat, C.; Jacqz-Aigrain, E. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr. Nephrol., 2003, 18 (9), 943-948.
35. Kedhar, S.R; Jabs, D.A. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes, 2007, 14 (3), 66-71.
36. Paya, C.; Humar, A.; Dominguez, E.; Washburn, K.; Blumberg, E.; Alexander, B.; Freeman, R.; Heaton, N.; Pescovitz, M.D. on behalf of the Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant., 2004, 4 (4), 611-620.
37. Roche Pharmaceuticals in the USA. FDA approves Valcyte® (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in pediatric patients who receive heart or kidney transplants. August 3, 2009 Hoffman-La Roche, Inc. http://www.rocheusa.com/ [Accessed 10th August, 2010].
38. Cvetković, R.S.; Wellington, K. Valganciclovir: A review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs, 2005, 65 (6), 859-878.
39. Galli, L.; Novelli, A.; Chiappini, E.; Gervaso, P.; Cassetta, M.I.; Fallani, S.; de Martino, M. Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. Pediatr. Infect. Dis. J., 2007, 26 (5), 451-453.
40. Acosta, E.P.; Brundage, R.C.; King, J.R.; Sánchez, P.J.; Sood, S.; Agrawal, V.; Homans, J.; Jacobs, R.F.; Lang, D.; Romero, J.R.; Griffin, J.; Cloud, G.; Whitley, R.; Kimberlin, D.W.; for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin. Pharmacol. Ther., 2007, 81 (6), 867-872.
41. Lalezari J.; Lindley J.; Walmsley S.; Kuppermann B.; Fisher M.; Friedberg D.; Lalonde R.; Matheron S.; Nieto L.; Torriani F.J.; Van Syoc R.; Sutton M.A.; Buhles W.; Stempien M.J.; for the Roche Valganciclovir Study Group. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J. Acquir. Immune Defic. Syndr., 2002, 30 (4), 392-400
42. Kalil, A.C.; Freifeld, A.G.; Lyden, E.R.; Stoner, J.A. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One, 2009; 4 (5), e5512.
43. ® (foscarnet sodium). http://dailymed.nlm.nih.gov/dailymed/getFile.cfm?id=5725&type= pdf&name=e177c228-33e1-4074-3e98-7d484c370e58 [Accessed 24th September, 2010].
44. Wagstaff, A.J.; Bryson, H.M. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs, 1994, 48 (2), 199-226.
45. Crumpacker, C.S. Mechanism of action of foscarnet against viral polymerases. Am. J. Med., 1992, 92 (2A), 3S-7S.
46. Aweeka, F.; Gambertoglio, J.; Mills, J.; Jacobson, M.A. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob. Agents Chemother., 1989, 33 (5), 742-745.
47. Arevalo, J.F.; Gonzalez, C.; Capparelli, E.V.; Kirsch, L.S.; Garcia, R.F.; Quiceno, J.I.; Connor, J.D.; Gambertoglio, J.; Bergeron-Lynn, G.; Freeman, W.R. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J. Infect. Dis., 1995, 172 (4), 951-956.
48. Nigro, G.; Sali, E.; Anceschi, M.M.; Mazzocco, M.; Maranghi, L.; Clerico, A.; Castello, M.A. Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites. J. Matern. Fetal Neonatal Med., 2004, 15 (5), 325-329.
49. Safrin, S.; Cherrington, J.; Jaffe, H.S. Clinical uses of cidofovir. Rev. Med. Virol., 1997, 7 (3), 145-156.
50. Package insert. Vistide ®(cidofovir injection). http://www.gilead.com/pdf/vistide.pdf [Accessed 24th September, 2010].
51. Polis, M.A.; Spooner, K.M.; Baird, B.F.; Manischewitz, J.F.; Jaffe, H.S.; Fisher, P.E.; Falloon, J.; Davey, R.T., Jr.; Kovacs, J.A.; Walker, R.E.; Whitcup, S.M.; Nussenblatt, R.B.; Lane, H.C.; Masur, H. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother., 1995, 39 (4), 882-886.
52. Lalezari, J.P.; Stagg, R.J.; Kuppermann, B.D.; Holland, G.N.; Kramer, F.; Ives, D.V.; Youle, M.; Robinson, M.R.; Drew, W.L.; Jaffe, H.S. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med., 1997, 126 (4), 257-263.
53. Stewart, M.W. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin. Ophthalmol., 2010, 4, 285-299.
54. Kaplan, J.E.; Benson, C.; Holmes, K.H.; Brooks, J.T.; Pau, A.; Masur, H.; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep., 2009, 58 (RR-4), 1-207.
55. Gallant, J.E.; Moore, R.D.; Richman, D.D.; Keruly, J.; Chaisson R.E.; and the Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J. Infect. Dis., 1992, 166 (6), 1223-1227.
56. Goldberg, D.E.; Smithen, L.M.; Angelilli, A.; Freeman, W.R. HIVassociated retinopathy in the HAART era. Retina, 2005, 25 (5), 633-649.
57. Drew, W.L. Cytomegalovirus infections in patients with AIDS. Clin. Infect. Dis., 1992, 14 (2), 608-615.
58. Palella, F.J., Jr.; Delaney, K.M.; Moorman, A.C.; Loveless, M.O.; Fuhrer, J.; Satten, G.A.; Aschman, D.J.; Holmberg, S.D.; and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med., 1998, 338 (13), 853-860.
59. Jacobson M.A. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med., 1997, 337 (2), 105-114. Erratum in: N. Engl. J. Med., 1997, 337 (14), 1019.
60. Holland, G.N. AIDS and ophthalmology: the first quarter century. Am. J. Ophthalmol., 2008, 145 (3), 397-408.
61. Drew, W.L.; Ives, D.; Lalezari, J.P.; Crumpacker, C.; Follansbee, S.E.; Spector, S.A.; Benson, C.A.; Friedberg, D.N.; Hubbard, L.; Stempien, M.J.; Shadman, A.; Buhles, W.; and the Syntex Cooperative Oral Ganciclovir Study Group. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. New. Engl. J. Med., 1995, 333 (10), 615-620.
62. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Mortality in patient with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N. Engl. J. Med., 1992, 326 (4), 213-220. Erratum in: N. Engl. J. Med., 1992, 326 (17), 1172.
63. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch. Ophthalmol., 1996, 114 (1), 23-33.
64. Lalezari, J.P.; Stagg, R.J.; Kuppermann, B.D.; Holland, G.N.; Kramer, F.; Ives, D.V.; Youle, M.; Robinson, M.R.; Drew, W.L.; Jaffe, H.S. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med., 1997, 126 (4), 257-263.
65. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann. Intern. Med., 1997, 126 (4), 264-274.
66. Martin, D.F.; Parks, D.J.; Mellow, S.D.; Ferris, F.L.; Walton, R.C.; Remaley, N.A.; Chew, E.Y.; Ashton, P.; Davis, M.D.; Nussenblatt, R.B. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch. Ophthalmol., 1994, 112 (12), 1531-1539.
67. Marx, J.L.; Kapusta, M.A.; Patel, S.S.; LaBree, L.D.; Walonker, F.; Rao, N.A.; Chong, L.P. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch. Ophthalmol., 1996, 114 (7), 815-820.
68. Martin, D.F.; Kuppermann, B.D.; Wolitz, W.A.; Palestine, A.G.; Li, H.; Robinson, C.A.; for the Roche Ganciclovir Study Group. Oral ganciclovir for patients with cytomegalovirus retinitis treated with the ganciclovir implant. N. Engl. J. Med., 1999, 340 (14), 1063-1070.
69. Martin, D.F.; Sierra-Madero, J.; Walmsley, S.; Wolitz, R.A.; Macey, K.; Georgiou, P.; Robinson, C.A.; Stempien, M.J.; for the Valganciclovir Study Group. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med., 2002, 346 (15), 1119-1126. Erratum in: N. Engl. J. Med., 2002, 347 (11), 862.
70. Russell, M.Y.; Palmer, A.; Michaels, M.G. Cytomegalovirus infection in pediatric immunocompromised hosts. Infect. Disord. Drug Targets, 2011, 11, 437-448.
71. Musch, D.C.; Martin, D.F.; Gordon, J.F.; Davis, M.D.; Kuppermann, B.D.; for the Ganciclovir Implant Study Group. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N. Engl. J. Med., 1997, 337 (2), 83-90.
72. Kempen, J.H.; Jabs, D.A.; Wilson, L.A.; Dunn, J.P.; West, S.K.; Tonascia, J. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin. Infect. Dis., 2003, 37 (10), 1365-1373.
73. Tural, C.; Romeu, J.; Sirera, G.; Andreu, D.; Conejero, M.; Ruiz, S.; Jou, A.; Bonjoch, A.; Ruiz, L.; Arnó, A.; Clotet, B. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J. Infect. Dis., 1998, 177 (4), 1080-1083.
74. Macdonald, J.C.; Torriani, F.J.; Morse, L.S.; Karavellas, M.P.; Reed, J.B.; Freeman, W.R. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J. Infect. Dis., 1998; 177 (5), 1182-1187.
75. Whitcup, S.M.; Fortin, E.; Lindblad, A.S.; Griffiths, P.; Metcalf, J.A.; Robinson, M.R.; Manischewitz, J.; Baird, B.; Perry, C.; Kidd, I.M.; Vrabec, T.; Davey, R.T., Jr.; Falloon, J.; Walker, R.E.; Kovacs, J.A.; Lane, H.C.; Nussenblatt, R.B.; Smith, J.; Masur, H.; Polis, M.A. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA, 1999, 282 (17), 1633-1637.
76. Jabs, D.A.; Bolton, S.G.; Dunn, J.P.; Palestine, A.G. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am. J. Ophthalmol., 1998, 126 (6), 817-822.
77. Jabs, D.A; Van Natta, M.L.; Holbrook, J.T.; Kempen, J.H.; Meinert, C.L.; Davis, M.D.; for the Studies of the Ocular Complications of AIDS Research Group. Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. Ophthalmology, 2007, 114 (4), 787-793.
78. Kempen, J.H.; Frick, K.D.; Jabs, D.A. Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS. Pharmacoeconomics, 2001, 19 (12), 1199-1208.
79. Ljungman, P.; Griffiths, P.; Paya, C. Definitions of cytomegalovirus infections and disease in transplant recipients. Clin. Infect. Dis., 2002, 34 (8), 1094-1097.
80. Singh, N. Cytomegalovirus infection in solid organ transplantation recipients: new challenges and their implications for preventive strategies. J. Clin. Virol., 2006, 35 (4), 474-477.
81. Rowshani, A.T.; Bemelman, F.J.; van Leeuwen, E.M.M.; van Lier, R.A.W.; ten Berge, I.J.M. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation, 2005, 79 (4), 381-386.
82. Singh, N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin. Infect. Dis., 2001, 32 (5), 742-751.
83. Singh, N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin. Infect. Dis., 2005, 40 (5), 704-708.
84. Snydman, D.R. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin. Infect. Dis., 2005, 40 (5), 709-712.
85. Snydman, D.R. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev. Med. Virol., 2006, 16 (5), 289-295.
86. Kalil, A.C.; Levitsky, J.; Lyden, E.; Stoner, J.; Freifield, A.G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med., 2005, 143 (12), 870-880.
87. Fishman, J.A. Infection in solid-organ transplant recipients. N. Engl. J. Med., 2007, 357 (25), 2601-2614.
88. Snydman, D.R. Persistent clinical impact of cytomegalovirus in organ transplantation. Clin. Infect. Dis., 2008, 47 (7), 883-884.
89. Sun, H.-Y.; Singh, N. Pharmacotherapy of post-transplant viral infections. Expert Opin. Pharmacother., 2008, 9 (14), 2409-2421.
90. Torres-Madriz, G.; Boucher, H.W. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin. Infect. Dis., 2008, 47 (5), 702-711.
91. Meyers, J.D.; Reed, E.C.; Shepp, D.H.; Thornquist, M.; Dandliker, P.S.; Vicary, C.A.; Flournow, N.; Kirk, L.E.; Kersey, J.H.; Thomas, E.D.; Balfour, H.H., Jr. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N. Engl. J. Med., 1988, 318 (2), 70-75.
92. Balfour, H.H., Jr.; Chace, B.A.; Stapleton, J.T.; Simmons, R.L.; Fryd, D.S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med., 1989, 320 (21), 1381-1387.
93. Prentice, H.G.; Gluckman, E.; Powles, R.L.; Ljungman, P.; Milpied, N.J.; Fernandez Rañada, J.M.F.; Mandelli, F.; Kho, P.; Kennedy, L.; Bell, A.R.; for the European Acyclovir for CMV Prophylaxis Study Group. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet, 1994, 343 (8900), 749-753.
94. Winston, D.J.; Wirin, D.; Shaked, A.; Busuttil, R.W. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet, 1995, 346 (8967), 69-74.
95. Gane, E.; Saliba, F.; Valdecasas, G.-J.; O'Grady, J.; Pescovitz, M.D.; Lyman, S.; Robinson, C.A.; for the Oral Ganciclovir International Transplantation Study Group. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet, 1997, 350 (9093), 1729-1733.
96. Hodson, E.M.; Jones, C.A.; Webster, A.C.; Strippoli, G.F.M.; Barclay, P.G.; Kable, K.; Vimalachandra, D.; Craig, J.C. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet, 2005, 365 (9477), 2105-2115.
97. Hodson, E.M.; Craig, J.C.; Strippoli, G.F.M.; Webster, A.C. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev., 2008, (2), CD003774.
98. Levitsky, J.; Singh, N.; Wagener, M.M.; Stosor, V.; Abecassis, M.; Ison, M.G. A survey of CMV prevention strategies after liver transplantation. Am. J. Transplant., 2008, 8 (1), 158-161.
99. Baliga, R.S.; Kadambi, P.V.; Javaid, B.; Harland R.; Williams J.W.; Thistlethwaite, J.R.; Josephson, M.A. A nationwide survey of cytomegalovirus prophylaxis and treatment in the transplant community. Am. J. Transplant., 2004, 4 (Suppl. s8), 495 (Abstract 1232).
100. Small, L.N.; Lau, J.; Snydman, D.R. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a metaanalysis comparing prophylactic and preemptive therapies. Clin. Infect. Dis., 2006, 43 (7), 869-880.
101. American Society of Transplantation. Cytomegalovirus. Am. J. Transplant., 2004, 4 (Suppl. 10), 51-58.
102. Preiksaitis, J.K.; Brennan, D.C.; Fishman, J.; Allen, U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am. J. Transplant., 2005, 5 (2), 218-227. Erratum in: Am. J. Transplant., 2005, 5 (3), 635.
103. Kotton, C.N.; Kumar, D.; Caliendo, A.M.; Åsberg, A.; Chou, S.; Snydman, D.R.; Allen, U.; Humar, A.; for the Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation, 2010, 89 (7), 779-795.
104. Åsberg, A.; Humar, A.; Rollag, H.; Jardine, A.G.; Mouas, H.; Pescovitz, M.D.; Sgarabotto, D.; Tuncer, M.; Noronha, I.L.; Hartmann, A.; for the VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant., 2007, 7 (9), 2106-2113.
105. Zamora, M.R.; Davis, R.D.; Leonard, C.; for the CMV Advisory Board Expert Committee. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation, 2005, 80 (2), 157-163. Erratum in: Transplantation, 2005, 80 (4), 545.
106. Meyers, J.D.; Flournoy, N.; Thomas, E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis., 1986, 153 (3), 478-488.
107. Marty, F.M.; Baden, L.R. Infection in the Hematopoietic Stem Cell Transplant Recipient. In: Hematopoietic Stem Cell Transplantation, 2nd ed.; Soiffer, Ed.; Humana Press: Totowa, NJ, 2008, pp. 421-448.
108. Goodrich, J.M.; Bowden, R.A.; Fisher, L.; Keller, C.; Schoch, G.; Meyers, J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med., 1993, 118 (3), 173-178.
109. Boeckh, M.; Nichols, W.G.; Papanicolaou, G.; Rubin, R.; Wingard, J.R.; Zaia, J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant., 2003, 9 (9), 543-558.
110. Crumpacker, C.; Marlowe, S.; Zhang, J.L.; Abrams, S.; Watkins, P. Treatment of cytomegalovirus pneumonia. Rev. Infect. Dis., 1988, 10 (Suppl 3), S538-S546.
111. Reed, E.C.; Bowden, R.A; Dandliker, P.S.; Lilleby, K.E.; Meyers, J.D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med., 1988, 109 (10), 783-788.
112. Schmidt, G.M.; Kovacs, A.; Zaia, J.A.; Horak, D.A.; Blume, K.G.; Nademanee, A.P.; O'Donnell, M.R., Snyder, D.S., Forman, S.J. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation, 1988, 46 (6), 905-907.
113. Tomblyn, M.; Chiller, T.; Einsele, H.; Gress, R.; Sepkowitz, K.; Storek, J.; Wingard, J.R.; Young, J-A.H.; Boeckh, M.J.; Center for International Blood and Marrow Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infecttious Diseases Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant., 2009, 15 (10). 1143-1238.
114. Zaia, J.; Baden, L.; Boeckh, M.J.; Chakrabarti, S.; Einsele, H.; Ljungman, P.; McDonald, G.B.; Hirsch, H.; Center for International Blood and Marrow Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infecttious Diseases Canada; Centers for Disease Control and Prevention. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant., 2009, 44 (8), 471-482.
115. Winston, D.J.; Yeager, A.M.; Chandrasekar, P.H.; Snydman, D.R.; Peterson, F.B.; Territo, M.C.; for the Valacyclovir Cytomegalovirus Study Group. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin. Infect. Dis., 2003, 36 (6), 749-758.
116. Winston, D.J.; Young, J-A.H.; Pullarkat, V.; Papanicolaou, G.A; Vij, R.; Vance, E.; Alangaden, G.J.; Chemaly, R.F.; Peterson, F.; Chao, N.; Klein, J.; Sprague, K.; Villano, S.A.; Boeckh, M. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood, 2008, 111 (11), 5403-5410.
117. The Medical News. ViroPharma reports results of trial of maribavir in bone marrow transplant recipients. http://www.newsmedical. net/news/2009/02/10/45809.aspx [Accessed 1st August, 2010].
118. Goodrich, J.M.; Mori, M.; Gleaves, C.A.; Du Mond, C.; Cays, M.; Ebeling, D.F.; Buhles, W.C.; DeArmond, B.; Meyers, J.D. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N. Engl. J. Med., 1991, 325 (23), 1601-1607.
119. Winston, D.J.; Ho, W.G., Bartoni, K.; Du Mond, C.; Ebeling, D.F.; Buhles, W.C.; Champlin, R.E. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann. Intern. Med., 1993, 118 (3), 179-184.
120. Boeckh, M.; Gooley, T.A.; Myerson, D.; Cunningham, T.; Schoch, G.; Bowden, R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood, 1996, 88 (10), 4063-4071.
121. Einsele, H.; Ehninger, G.; Hebart, H.; Wittkowski, K.M.; Schuler, U.; Jahn, G.; Mackes, P.; Herter, M.; Klingebiel, T.; Löffler, J.; Wagner, S; Müller, C.A. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood, 1995, 86 (7), 2815-2820.
122. Reusser, P.; Einsele, H.; Lee, J.; Volin, L.; Rovira, M.; Engelhard, D.; Finke, J.; Cordonnier, C.; Link, H.; Ljungman, P.; for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood, 2002, 99 (4), 1159-1164.
123. Mattes, F.M.; Hainsworth, E.G.; Geretti, A.M.; Nebbia, G.; Prentice, G.; Potter, M.; Burroughs, A.K.; Sweny, P.; Hassan-Walker, A.F.; Okwuadi, S.; Sabin, C.; Amooty, G.; Brown, V.S.; Grace, S.C.; Emery, V.C.; Griffiths, P.D. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at halfdose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J. Infect. Dis., 2004, 189 (8), 1355-1361.
124. Ljungman, P.; Deliliers, G.L.; Platzbecker, U.; Matthes-Martin, S.; Bacigalupo, A.; Einsele, H.; Ullmann, J.; Musso, M.; Trenschel, R.; Ribaud, P.; Bornhäuser, M.; Cesaro, S.; Crooks, B.; Dekker, A.; Gratecos, N.; Klingebiel, T.; Tagliaferri, E.; Ullmann, A.J.; Wacker, P.; Cordonnier, C.; for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood, 2001, 97 (2), 388-392.
125. Volin, L.; Barkholt, L.; Nihtinen, A.; Aschan, J.; Uotinen, H.; Hägglund, H.; Juvonen, E.; Ringdén, O.; Ruutu, T.; Ljungman, P. An open-label randomised study of oral valganciclovir versus intravenous ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant., 2008, 41 (Suppl. 1), 47 (Abstract 0268).
126. Maschmann, J.; Hamprecht, K.; Dietz, K.; Jahn, G.; Speer, C.P. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin. Infect. Dis., 2001, 33 (12), 1998-2003.
127. Vollmer, B.; Seibold-Weiger, K.; Schmitz-Salue, C.; Hamprecht, K.; Goelz, R.; Krageloh-Mann, I.; Speer, C.P. Postnatally acquired cytomegalovirus infection via breast milk: effects on hearing and development in preterm infants. Pediatr. Infect. Dis. J., 2004, 23 (4), 322-327.
128. Kenneson, A.; Cannon, M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol., 2007, 17 (4), 253-276.
129. Dollard, S.C.; Grosse, S.D.; Ross, D.S. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol., 2007, 17 (5), 355-363.
130. Michaels, M.G.; Greenberg, D.P.; Sabo, D.L.; Wald, E.R. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr. Infect. Dis. J., 2003, 22 (6), 504-509.
131. Nigro, G.; Scholz, H.; Bartmann, U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a tworegimen experience. J. Pediatr., 1994, 124 (2), 318-322.
132. Whitley, R.J.; Cloud, G.; Gruber, W.; Storch, G.A.; Demmler, G.J.; Jacobs, R.F.; Dankner, W.; Spector, S.A.; Starr, S.; Pass, R.F.; Stagno, S.; Britt, W.J.; Alford, C. Jr.; Soong, S.; Zhou, X.J.; Sherrill, L.; FitzGerald, J.M.; Sommadossi, J.P.; for the National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. J. Infect. Dis., 1997, 175 (5), 1080-1086.
133. Gilbert, C.; Boivin, G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother., 2005, 49 (3), 873-883.
134. Erice, A. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev., 1999, 12 (2), 286-297.
135. Limaye, A.P.; Corey, L.; Koelle, D.M.; Davis, C.L.; Boeckh, M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, 2000, 356 (9230), 645-649.
136. Limaye, A.P. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis., 2002, 35 (7), 866-872.
137. Chou, S.; Erice, A.; Jordan, M.C.; Vercellotti, G.M.; Michaels, K.R.; Talarico, C.L.; Stanat, S.C.; Biron, K.K. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis., 1995, 171 (3), 576-583.
138. Avery, R.K. Update in management of ganciclovir-resistant cytomegalovirus infection. Curr. Opin. Infect. Dis., 2008, 21 (4), 433-437.
139. Drew, W.L. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin. Infect. Dis., 2010, 50 (5), 733-736.
140. Smith, I.L.; Cherrington, J.M.; Jiles, R.E.; Fuller, M.D.; Freeman, W.R.; Spector, S.A. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis., 1997, 176 (1), 69-77. Erratum in: J. Infect. Dis., 1997, 177 (4), 1140-1141.
141. Erice, A; Chou, S.; Biron, K.K.; Stanat, S.C.; Balfour, H.H., Jr.; Jordan, M.C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med., 1989, 320 (5), 289-293.
142. Drew, W.L.; Miner, R.C.; Busch, D.F.; Follansbee, S.E.; Gullett, J.; Mehalko, S.G.; Gordon, S.M.; Owen, W.F., Jr.; Matthews, T.R.; Buhles, W.C.; DeArmond, B. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis., 1991, 163 (4), 716-719.
143. Martin, B.K.; Ricks, M.O.; Forman, M.S.; Jabs, D.A.; for the Cytomegalovirus Retinitis and Viral Resistance Study Group. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin. Infect. Dis., 2007, 44 (7), 1001-1008.
144. Boivin, G.; Goyette, N.; Gilbert, C.; Roberts, N.; Macey, K.; Paya, C.; Pescovitz, M.D.; Humar, A.; Dominguez, E.; Washburn, K.; Blumberg, E.; Alexander, B.; Freeman, R.; Heaton, N.; Covington, E. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solidorgan transplant recipients. J. Infect. Dis., 2004, 189 (9), 1615-1618.
145. Sudarsanam, T. D.; Sahni, R.D.; John, G.T. Leflunomide: a possible alternative for ganciclovir sensitive and resistant cytomegalovirus infections. Postgrad. Med. J., 2006, 82 (967), 313-314.
146. Efferth, T.; Romero, M.R.; Wolf, D.G.; Stamminger, T.; Marin, J.J.G.; Marschall, M. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis., 2008, 47 (6), 804-811.
147. Shapira, M.Y.; Resnick, I.B.; Chou, S.; Neumann, A.U; Lurain, N.S.; Stamminger, T.; Caplan, O.; Saleh, N.; Efferth, T.; Marschall, M.; Wolf, D.G. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis., 2008, 46 (9), 1455-1457.
148. Biron, K.K.; Harvey, R.J.; Chamberlain, S.C.; Good, S.S.; Smith, A.A., 3rd; Davis, M.G.; Talarico, C.L.; Miller, W.H.; Ferris, R.; Dornsife, R.E.; Stanat, S.C; Drach, J.C.; Townsend, L.B.; Koszalka, G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother., 2002, 46 (8), 2365-2372.
149. Trofe, J.; Pote, L.; Wade, E.; Blumberg, E.; Bloom, R.D. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann. Pharmacother., 2008, 42 (10), 1447-1457.
150. Wang, L.H.; Peck, R.W.; Yin, Y.; Allanson, J.; Wiggs, R.; Wire, M.B. Phase I study and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother., 2003, 47 (4), 1334-1342.
151. Lalezari, J.P.; Aberg, J.A.; Wang, L.H.; Wire, M.B.; Miner, R.; Snowden, W.; Talarico, C.L.; Shaw, S.; Jacobson, M.A.; Drew, W.L. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother., 2002, 46 (9), 2969-2976.
152. Chou, S.; Van Wechel, L.C.; Marousek, G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis., 2007, 196 (1), 91-94.
153. Ciesla, S.L.; Trahan, J.; Wan, W.B.; Beadle, J.R.; Aldern, K.A.; Painter, G.R.; Hostetler, K.Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res., 2003; 59 (3), 163-171.
154. Chimerix. www.chimerix-inc.com/therapeutic-programs [Accessed 6th August, 2010].